p53 and MDM2: Antagonists or Partners in Crime?

Christine M. Eischen, Guillermina Lozano

Research output: Contribution to journalShort survey

37 Scopus citations

Abstract

Therapeutics that disrupt the p53-MDM2 interaction show promise for cancer treatment but surprisingly have different biological outcomes. A study by Enge et al. in this issue of Cancer Cell shows that the ability of MDM2 to target hnRNP K for degradation contributes to the decision to induce apoptosis rather than cell-cycle arrest.

Original languageEnglish (US)
Pages (from-to)161-162
Number of pages2
JournalCancer cell
Volume15
Issue number3
DOIs
StatePublished - Mar 3 2009

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Cite this